AIRLINK 72.80 Increased By ▲ 0.62 (0.86%)
BOP 5.06 Increased By ▲ 0.13 (2.64%)
CNERGY 4.33 Decreased By ▼ -0.02 (-0.46%)
DFML 30.52 Increased By ▲ 2.03 (7.13%)
DGKC 85.95 Increased By ▲ 4.65 (5.72%)
FCCL 22.35 Increased By ▲ 0.85 (3.95%)
FFBL 33.22 Increased By ▲ 0.17 (0.51%)
FFL 9.78 Decreased By ▼ -0.08 (-0.81%)
GGL 10.40 Decreased By ▼ -0.08 (-0.76%)
HBL 113.62 Decreased By ▼ -0.38 (-0.33%)
HUBC 136.20 Decreased By ▼ -3.80 (-2.71%)
HUMNL 10.03 Increased By ▲ 1.00 (11.07%)
KEL 4.66 Decreased By ▼ -0.07 (-1.48%)
KOSM 4.40 Increased By ▲ 0.02 (0.46%)
MLCF 38.35 Increased By ▲ 0.70 (1.86%)
OGDC 133.40 Decreased By ▼ -0.30 (-0.22%)
PAEL 27.40 Increased By ▲ 1.80 (7.03%)
PIAA 24.76 Increased By ▲ 0.78 (3.25%)
PIBTL 6.55 Increased By ▲ 0.07 (1.08%)
PPL 121.21 Decreased By ▼ -1.41 (-1.15%)
PRL 27.15 Increased By ▲ 0.08 (0.3%)
PTC 13.89 Increased By ▲ 0.29 (2.13%)
SEARL 60.40 Increased By ▲ 3.78 (6.68%)
SNGP 68.53 Decreased By ▼ -0.71 (-1.03%)
SSGC 10.33 Decreased By ▼ -0.01 (-0.1%)
TELE 9.05 Increased By ▲ 0.60 (7.1%)
TPLP 11.26 Decreased By ▼ -0.02 (-0.18%)
TRG 65.70 Increased By ▲ 4.49 (7.34%)
UNITY 25.25 Decreased By ▼ -0.08 (-0.32%)
WTL 1.50 No Change ▼ 0.00 (0%)
BR100 7,608 Decreased By -22.2 (-0.29%)
BR30 25,091 Increased By 100.6 (0.4%)
KSE100 72,658 Increased By 56.2 (0.08%)
KSE30 23,383 Decreased By -155.9 (-0.66%)
Pakistan Print 2019-12-18

ICI Pakistan strengthens its partnership with AstraZeneca

ICI Pakistan Limited and AstraZeneca UK Limited confirmed the renewal of their longstanding relationship in the cardiovascular and oncology segment. ICI Pakistan is a longstanding distributor of AstraZeneca's high quality life-saving medicines. AstraZenec
Published 18 Dec, 2019 12:00am

ICI Pakistan Limited and AstraZeneca UK Limited confirmed the renewal of their longstanding relationship in the cardiovascular and oncology segment. ICI Pakistan is a longstanding distributor of AstraZeneca's high quality life-saving medicines. AstraZeneca GCC Country President Ismail Shehada visited ICI Pakistan and met with key stakeholders during his two-day visit to renew the existing relationship and explore potential new avenues of partnership to alleviate suffering and build a platform for patients and caregivers to treat high burden of diseases in Pakistan.

Gracing the ceremony at the ICI Pakistan Head Office, Mike Nithavrianakis, British Deputy High Commissioner Karachi and Trade Director for Pakistan, emphasised the importance of building a sustainable ecosystem to provide much needed care to patients in Pakistan.

Speaking on the occasion, ICI Pakistan Chief Executive Asif Jooma said, "ICI Pakistan has been in the pharmaceuticals business since 1993 and seeks to further enhance its global partnerships and introduce innovative products."

Shehada added, "AstraZeneca has an interest in the region and intends to grow its business through providing improved solutions for patients." He further stated, "AstraZeneca is a full healthcare company providing not only innovative molecules but which believes in going beyond medication alone by looking to introduce customised solutions to meet local needs and requirements."-PR

Copyright Business Recorder, 2019

Comments

Comments are closed.